Czy oznaczanie osoczowego stężenia naczyniowo- -śródbłonkowego czynnika wzrostu będzie w przyszłości wartościowym parametrem w ocenie chorych z miażdżycą tętnic kończyn dolnych w praktyce lekarza rodzinnego? – badanie pilotażowe

• Authors: Wieczór Radosław , Budzyński Jacek , Pulkowski Grzegorz , Rość Danuta
• Languages of publication: PL

Keywords

miażdżyca tętnic kończyn dolnych; naczyniowo-śródbłonkowy czynnik wzrostu; wskaźnik kostka–ramię; chromanie przestankowe; biomarker

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2015
• Issue: 2
• Pages: 131-135

Contributors

author

Wieczór Radosław

author

Budzyński Jacek

author

Pulkowski Grzegorz

author

Rość Danuta

References

• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the management of peripheral arterial disease (TASC II ). Eur J Vasc Endovasc Surg 2007; 33(1): 1–75.
• Tendera M, Aboyans V, Bartrelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC ). Eur Heart J 2011; 32: 2851–2906.
• Kontos CD , Annex BH. Angiogenesis. Curr Atheroscler Rep 1999; (1)2: 165–171.
• Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23(7): 1143–1151.
• Folkman J. Tumor angiogenesis: therapeutic implications. N Eng J Med 1971; 285(21): 1182–1186.
• Zielonka TM. Angiogenesis – Part I. Mechanism of neovascularization. Alergia Astma Immunol 2003; 8(4): 169–174.
• Barańska P, Jerczyńska H, Pawłowska Z. Vascular endothelial growth factor – structure and functions. Post Biochem 2005;51(1): 12–21.
• Brandao D, Costa C, Canedo A, et al. Endogenous vascular endothelial growth factor and angiopoietin-2 expression in critical limb ischemia. Int Angiol 2011; 30(1): 25–34.
• Findley CM, Mitchell RG, Duscha BD, et al. Plasma levels of soluble tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 2008; 52(5):387–393.
• Blann AD , Belgore FM, McCollum CN , et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci 2002; 102: 187–194.
• Stehr A, Töpel I, Müller, S et al. VEGF: a surrogate marker for peripheral vascular disease. Eur J Vasc Endovasc Surg 2010; 39:330–332.
• Matsui K, Yoshioka T, Murakami Y, et al. Serum concetrations of vascular endothelial growth factor and monocyte-colony stimulating factor in peripheral arterial disease. Circ J 2003; 67: 660–662.
• Proczka RM, Małecki M, Chrostowska-Wynimko J, Polański JA. Vascular endothelial growth factor (VEGF) in patients with peripheral ischemia. J Physiol Pharmacol 2006; 57(4): 305–311.
• Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol 2010; 55(19): 2017–2023.
• Wieczór R, Gadomska G, Góralczyk B, et al. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease – preliminary report. Int Angiol 2014; Nov 14 [Epub ahead of print].
• Rość D, Wieczór R, Stankowska K, et al. Plasma VEGF-A/SVEGFR-1 ratio as a potential ischemic marker in patients with symptomatic peripheral arterial disease – preliminary report. Thromb Res 2014; 133(Suppl. 3): S95.
• Makin AJ, Chung NA , Silverman SH, et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artety disease: a link between angiogenesis and thrombogenesis? Clin Sci 2003; 104: 397–404